Neurology perspectives

Risk of infection and immunosuppression in relapsing–remitting multiple sclerosis treated with alemtuzumab: A 3.5-year follow-up study M.S. Fortes-González; L. Herrero-Poch; A. Pato-Pato; P. Gabeiras-Araújo; M. Lorenzo-García; D.A. García-Estévez; J.R. Lorenzo-González;

Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study Martinez-Gines; Garcia-Dominguez; J.P. Cuello; V. Meca-Lallana; C. Aguirre; L. Costa-Frossard; E. Monreal; S. Sainz de la Maza; Salgado-Camara; A. Labiano-Fontcuberta; Fernandez-Cabredo; Y. Aladro-Benito; L.B. Canelo; O.Sánchez-del Valle; M.R. Blasco; Sabin-Munoz; Caminero-Rodriguez; J. Gracia-Gil; E. Fernandez-Diaz; Mendoza-Rodriguez; Gomez-Moreno; Orviz-Garcia; I. Moreno-Torres; Casanova-Peno; A. Lozano-Ros;

Real-world data on the effectiveness and safety of teriflunomide in patients with relapsing–remitting multiple sclerosis: The EFFECT study Duran Herrera; Sanchez; E. Aguera; Munoz; A. Alonso; C. Arnal; J. Dotor; J. Barrero; Gomez; J. Caballero-Villarraso; Hernandez; E. Cancho; M. Romera; Gavilan; F. Castellanos; R. Espinosa; L. Forero; R. Querol-Pascual; A.M. Roa-Montero; de Colosia Rama; A.G. Plata; F.P. Parrado;